UNASSIGNED: Study Cohort: This study encompassed a cohort of 119 patients diagnosed with MMRd-EC between 2015 and 2022. Analyses using t-tests and Mann-Whitney U-tests were performed to assess prognostic markers and peripheral blood immune cell profiles in patients with MutS deficiency (MutS-d) versus those with MutL deficiency (MutL-d). Logistic regression analysis was used to identify independent risk factors. Bioinformatics Analysis: An online database was used to assess the prognostic implications, immune cell infiltration, and immune checkpoint involvement associated with the deficiency of MutS versus MutL in EC.
UNASSIGNED: Patients with MutL-d exhibited heightened risk factors, including elevated cancer grade and increased myometrial invasion, leading to poorer prognosis and shorter overall survival and progression-free survival. Regarding systemic immune status, patients with MutL-d demonstrated decreased peripheral blood lymphocyte percentage, lymphocyte count, and CD8+ T cell percentage. For local immunity, the infiltration of natural killer cells, CD8+ T cells, and cytotoxic T lymphocytes in the tumor tissue was reduced in patients with MutL-d. Additionally, patients with MutL-d exhibited lower expression of immune checkpoint markers. The composition of immune subtypes and survival outcomes also indicate that patients with MutL-d have a poorer immune status and prognosis than the patients with MutS-d.
UNASSIGNED: Patients with MMRd-EC can be subclassified according to MutS or MutL deficiency. Patients with MutS-d exhibited better immune status, prognosis, and immunotherapy benefits than those with MutL-d. These results can help guide patients to a more precise treatment.
■研究队列:该研究涵盖了2015年至2022年间诊断为MMRd-EC的119名患者的队列。使用t检验和Mann-WhitneyU检验进行分析,以评估MutS缺陷(MutS-d)患者与MutL缺陷(MutL-d)患者的预后标志物和外周血免疫细胞谱。采用Logistic回归分析确定独立危险因素。生物信息学分析:使用在线数据库评估预后影响,免疫细胞浸润,以及与EC中MutS和MutL缺乏相关的免疫检查点参与。
■MutL-d患者表现出升高的危险因素,包括癌症分级升高和肌层浸润增加,导致预后较差,总生存期和无进展生存期较短。关于全身免疫状态,MutL-d患者外周血淋巴细胞百分比降低,淋巴细胞计数,和CD8+T细胞百分比。为了当地豁免权,自然杀伤细胞的浸润,CD8+T细胞,MutL-d患者肿瘤组织中的细胞毒性T淋巴细胞减少。此外,MutL-d患者的免疫检查点标志物表达较低.免疫亚型的组成和生存结果也表明MutL-d患者的免疫状态和预后比MutS-d患者差。
■MMRd-EC患者可以根据MutS或MutL缺陷进行细分。MutS-d患者表现出更好的免疫状态,预后,和免疫疗法的好处比那些与MutL-d。这些结果可以帮助指导患者进行更精确的治疗。